Scancell Plc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Scancell plc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Scancell Plc Today - Breaking & Trending Today
Search jobs 06-May-2021 Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science ecosystem in collaboration with Bristol Myers Squibb DGAP-News: Evotec SE / Key word(s): Miscellaneous 06.05.2021 / 07:30 beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK THE COLLABORATION LEVERAGES EVOTEC S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR Hamburg, Germany, 06 May 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportuniti ....
Date Time Partnership launched to fast track drug discovery The University of Nottingham is part of a new industry collaboration launched to accelerate drug discovery projects that will fast track research from lab to patient. The University of Nottingham is one of four universities selected by drug development company Evotec SE and global pharmaceutical company Bristol Myers Squibb to be part of the newly formed beLAB1407. Evotec, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Nottingham, Birmingham, Edinburgh and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the crea ....